NewCardio Research Development from 2010 to 2024

NewCardio's Research Development is increasing with slightly volatile movements from year to year. Research Development is predicted to flatten to about 2.5 M. For the period between 2010 and 2024, NewCardio, Research Development quarterly trend regression had mean deviation of  505,307 and range of 3.8 M. View All Fundamentals
 
Research Development  
First Reported
2010-12-31
Previous Quarter
4.1 M
Current Value
2.5 M
Quarterly Volatility
880.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NewCardio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewCardio's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 5.6 M, as well as many indicators such as Price To Sales Ratio of 43.12, Dividend Yield of 0.0 or Days Sales Outstanding of 40.43. NewCardio financial statements analysis is a perfect complement when working with NewCardio Valuation or Volatility modules.
  
Check out the analysis of NewCardio Correlation against competitors.
For more detail on how to invest in NewCardio Stock please use our How to Invest in NewCardio guide.

Currently Active Assets on Macroaxis

When determining whether NewCardio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NewCardio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Newcardio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Newcardio Stock:
Check out the analysis of NewCardio Correlation against competitors.
For more detail on how to invest in NewCardio Stock please use our How to Invest in NewCardio guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewCardio. If investors know NewCardio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewCardio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
0.008
Quarterly Revenue Growth
(0.90)
Return On Assets
(2.24)
The market value of NewCardio is measured differently than its book value, which is the value of NewCardio that is recorded on the company's balance sheet. Investors also form their own opinion of NewCardio's value that differs from its market value or its book value, called intrinsic value, which is NewCardio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewCardio's market value can be influenced by many factors that don't directly affect NewCardio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewCardio's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewCardio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewCardio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.